Targeting cardiac natriuretic peptides in the therapy of diabetes and obesity

Expert Opinion on Therapeutic Targets

Volumn 20, Issue 12, 2016, Pages 1445-1452

  Moro, Cedric ^a,b  

^a Université de Toulouse   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

Author keywords

Adipose tissue; cGMP; fat oxidation; insulin resistance; lipolysis; skeletal muscle

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; ATRIAL NATRIURETIC FACTOR RECEPTOR; MEMBRANE METALLOENDOPEPTIDASE; NATRIURETIC PEPTIDE RECEPTOR C;

ADIPOSE TISSUE; BROWN ADIPOSE TISSUE; CLINICAL TRIAL (TOPIC); DOWN REGULATION; DRUG MECHANISM; DRUG TARGETING; HUMAN; INSULIN SENSITIVITY; LIPID METABOLISM; LIVER; METABOLIC DISORDER; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS; REVIEW; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; WHITE ADIPOSE TISSUE; ANIMAL; DEFICIENCY; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY;

ANIMALS; ATRIAL NATRIURETIC FACTOR; DIABETES MELLITUS, TYPE 2; HUMANS; MOLECULAR TARGETED THERAPY; NATRIURETIC PEPTIDE, BRAIN; NEPRILYSIN; OBESITY; RECEPTORS, ATRIAL NATRIURETIC FACTOR;

EID: 84995757446     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1080/14728222.2016.1254198     Document Type: Review

References (92)

1. De Bold AJ, Flynn TG., Cardionatrin I–a novel heart peptide with potent diuretic and natriuretic properties. Life Sci. 1983;33:297–302.
2. Del Ry S, Cabiati M, Vozzi F, et al. Expression of C-type natriuretic peptide and its receptor NPR-B in cardiomyocytes. Peptides. 2011;32:1713–1718.
3. Gardner DG, Chen S, Glenn DJ, et al. Molecular biology of the natriuretic peptide system:implications for physiology and hypertension. Hypertension. 2007;49:419–426.
4. Potter LR. Natriuretic peptide metabolism, clearance and degradation. Febs J. 2011;278:1808–1817.
5. Gardner DG. Natriuretic peptides:markers or modulators of cardiac hypertrophy? Trends Endocrinol Metab. 2003;14:411–416.
6. Pandey KN. Guanylyl cyclase/atrial natriuretic peptide receptor-A:role in the pathophysiology of cardiovascular regulation. Can J Physiol Pharmacol. 2011;89:557–573.
7. Potter LR, Abbey-Hosch S, Dickey DM. Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr Rev. 2006;27:47–72.
8. Ralat LA, Guo Q, Ren M, et al. Insulin-degrading enzyme modulates the natriuretic peptide-mediated signaling response. J Biol Chem. 2011;286:4670–4679.
9. Clerico A, Fontana M, Vittorini S, et al. The search for a pathophysiological link between gender, cardiac endocrine function, body mass regulation and cardiac mortality:proposal for a working hypothesis. Clin Chim Acta. 2009;405:1–7.
10. Clerico A, Passino C, Emdin M. When gonads talk to the heart sex hormones and cardiac endocrine function. J Am Coll Cardiol. 2011;58:627–628.
11. Anand-Srivastava MB. Natriuretic peptide receptor-C signaling and regulation. Peptides. 2005;26:1044–1059.
12. Kita S, Nishizawa H, Okuno Y, et al. Competitive binding of musclin to natriuretic peptide receptor 3 with atrial natriuretic peptide. J Endocrinol. 2009;201:287–295.
13. Florkowski CM, Richards AM, Espiner EA, et al. Renal, endocrine, and hemodynamic interactions of atrial and brain natriuretic peptides in normal men. Am J Physiol. 1994;266:R1244–R50.
14. Matsukawa N, Grzesik WJ, Takahashi N, et al. The natriuretic peptide clearance receptor locally modulates the physiological effects of the natriuretic peptide system. Proc Natl Acad Sci U S A. 1999;96:7403–7408.
15. Maack T, Suzuki M, Almeida FA, et al. Physiological role of silent receptors of atrial natriuretic factor. Science. 1987;238:675–678.
16. Nussenzveig DR, Lewicki JA, Maack T. Cellular mechanisms of the clearance function of type C receptors of atrial natriuretic factor. J Biol Chem. 1990;265:20952–20958.
17. Rathinavelu A, Isom GE. Differential internalization and processing of atrial-natriuretic-factor B and C receptor in PC12 cells. Biochem J. 1991;276(Pt 2):493–497.
18. Kukkonen P, Vuolteenaho O, Ruskoaho H. Basal and volume expansion-stimulated plasma atrial natriuretic peptide concentrations and hemodynamics in conscious rats:effects of SCH 39.370, an endopeptidase inhibitor, and C-ANF-(4-23), a clearance receptor ligand. Endocrinology. 1992;130:755–765.
19. Potter LR. Guanylyl cyclase structure, function and regulation. Cell Signal. 2011;23:1921–1926.
20. Asakura M, Jiyoong K, Minamino T, et al. Rationale and design of a large-scale trial using atrial natriuretic peptide (ANP) as an adjunct to percutaneous coronary intervention for ST-segment elevation acute myocardial infarction:Japan-working groups of acute myocardial infarction for the reduction of necrotic damage by ANP (J-WIND-ANP). Circ J. 2004;68:95–100.
21. O’Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011;365:32–43.
22. Suwa M, Seino Y, Nomachi Y, et al. Multicenter prospective investigation on efficacy and safety of carperitide for acute heart failure in the ‘real world’ of therapy. Circ J. 2005;69:283–290.
23. Elkayam U, Akhter MW, Tummala P, et al. Nesiritide:a new drug for the treatment of decompensated heart failure. J Cardiovasc Pharmacol Ther. 2002;7:181–194.
24. Moro C, Smith SR. Natriuretic peptides:new players in energy homeostasis. Diabetes. 2009;58:2726–2728.
25. Coue M, Moro C. Natriuretic peptide control of energy balance and glucose homeostasis. Biochimie. 2016;124:84–91.
26. Lafontan M, Moro C, Berlan M, et al. Control of lipolysis by natriuretic peptides and cyclic GMP. Trends Endocrinol Metab. 2008;19:130–137.
27. Moro C, Lafontan M. Natriuretic peptides and cGMP signaling control of energy homeostasis. Am J Physiol Heart Circ Physiol. 2013;304:H358–H68.
28. Sarzani R, Dessi-Fulgheri P, Salvi F, et al. A novel promoter variant of the natriuretic peptide clearance receptor gene is associated with lower atrial natriuretic peptide and higher blood pressure in obese hypertensives. J Hypertens. 1999;17:1301–1305.
29. Sarzani R, Strazzullo P, Salvi F, et al. Natriuretic peptide clearance receptor alleles and susceptibility to abdominal adiposity. Obes Res. 2004;12:351–356.
30. Cannone V, Boerrigter G, Cataliotti A, et al. A genetic variant of the atrial natriuretic peptide gene is associated with cardiometabolic protection in the general community. J Am Coll Cardiol. 2011;58:629–636.
31. Clerico A, Giannoni A, Vittorini S, et al. The paradox of low BNP levels in obesity. Heart Fail Rev. 2012;17:81–96.
32. Cabiati M, Belcastro E, Caselli C, et al. Endothelin system mRNA variation in the heart of Zucker rats:evaluation of a possible balance with natriuretic peptides. Nutr Metab Cardiovasc Dis. 2014;24:1166–1173.
33. Arora P, Wu C, Hamid T, et al. Acute metabolic influences on the natriuretic peptide system in humans. J Am Coll Cardiol. 2016;67:804–812.
34. Plante E, Menaouar A, Danalache BA, et al. Treatment with brain natriuretic peptide prevents the development of cardiac dysfunction in obese diabetic db/db mice. Diabetologia. 2014;57:1257–1267.
35. Yuan K, Yu J, Shah A, et al. Leptin reduces plasma ANP level via nitric oxide-dependent mechanism. Am J Physiol Regul Integr Comp Physiol. 2010;298:R1007–R16.
36. Zhang H, Thoonen R, Yao V, et al. Regulation of B-type natriuretic peptide synthesis by insulin in obesity in male mice. Exp Physiol. 2016;101:113–123.
37. Wang TJ, Larson MG, Levy D, et al. Impact of obesity on plasma natriuretic peptide levels. Circulation. 2004;109:594–600.• This study highlights the negative association between circulating NP levels and body mass index and, for the first time, the NP handicap in obesity.
38. Das SR, Drazner MH, Dries DL, et al. Impact of body mass and body composition on circulating levels of natriuretic peptides:results from the Dallas Heart Study. Circulation. 2005;112:2163–2168.
39. Khan AM, Cheng S, Magnusson M, et al. Cardiac natriuretic peptides, obesity, and insulin resistance:evidence from two community-based studies. J Clin Endocrinol Metab. 2011;96:3242–3249.
40. Taylor JA, Christenson RH, Rao K, et al. B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide are depressed in obesity despite higher left ventricular end diastolic pressures. Am Heart J. 2006;152:1071–1076.
41. Sarzani R, Dessi-Fulgheri P, Paci VM, et al. Expression of natriuretic peptide receptors in human adipose and other tissues. J Endocrinol Invest. 1996;19:581–585.
42. Sengenes C, Berlan M, De Glisezinski I, et al. Natriuretic peptides:a new lipolytic pathway in human adipocytes. Faseb J. 2000;14:1345–1351.
43. Miyashita K, Itoh H, Tsujimoto H, et al. Natriuretic peptides/cGMP/cGMP-dependent protein kinase cascades promote muscle mitochondrial biogenesis and prevent obesity. Diabetes. 2009;58:2880–2892.• This is an important piece of work showing the potential causal link between NP deficiency and T2D in various transgenic mouse models of the NP system.
44. Coue M, Badin PM, Vila IK, et al. Defective natriuretic peptide receptor signaling in skeletal muscle links obesity to type 2 diabetes. Diabetes. 2015;64:4033–4045.
45. Pivovarova O, Gogebakan O, Kloting N, et al. Insulin up-regulates natriuretic peptide clearance receptor expression in the subcutaneous fat depot in obese subjects:a missing link between CVD risk and obesity? J Clin Endocrinol Metab. 2012;97:E731–E9.
46. Moro C, Galitzky J, Sengenes C, et al. Functional and pharmacological characterization of the natriuretic peptide-dependent lipolytic pathway in human fat cells. J Pharmacol Exp Ther. 2004;308:984–992.
47. Sengenes C, Bouloumie A, Hauner H, et al. Involvement of a cGMP-dependent pathway in the natriuretic peptide-mediated hormone-sensitive lipase phosphorylation in human adipocytes. J Biol Chem. 2003;278:48617–48626.
48. Galitzky J, Sengenes C, Thalamas C, et al. The lipid-mobilizing effect of atrial natriuretic peptide is unrelated to sympathetic nervous system activation or obesity in young men. J Lipid Res. 2001;42:536–544.
49. Birkenfeld AL, Boschmann M, Moro C, et al. Lipid mobilization with physiological atrial natriuretic peptide concentrations in humans. J Clin Endocrinol Metab. 2005;90:3622–3628.
50. Birkenfeld AL, Boschmann M, Moro C, et al. Beta-adrenergic and atrial natriuretic peptide interactions on human cardiovascular and metabolic regulation. J Clin Endocrinol Metab. 2006;91:5069–5075.
51. Birkenfeld AL, Budziarek P, Boschmann M, et al. Atrial natriuretic peptide induces postprandial lipid oxidation in humans. Diabetes. 2008;57:3199–3204.
52. Moro C, Crampes F, Sengenes C, et al. Atrial natriuretic peptide contributes to physiological control of lipid mobilization in humans. Faseb J. 2004;18:908–910.
53. Engeli S, Birkenfeld AL, Badin PM, et al. Natriuretic peptides enhance the oxidative capacity of human skeletal muscle. J Clin Invest. 2012;122:4675–4679.• This work highlighted for the very first time a functional signaling pathway of NP in human skeletal muscle. It was shown that NP enhances mitochondrial oxidative capacity and fat oxidation in a similar fashion as exercise training.
54. Nishizawa H, Matsuda M, Yamada Y, et al. Musclin, a novel skeletal muscle-derived secretory factor. J Biol Chem. 2004;279:19391–19395.
55. Subbotina E, Sierra A, Zhu Z, et al. Musclin is an activity-stimulated myokine that enhances physical endurance. Proc Natl Acad Sci U S A. 2015;112:16042–16047.
56. Bordicchia M, Liu D, Amri EZ, et al. Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. J Clin Invest. 2012;122:1022–1036.• This study shows that NP controls a thermogenic program in white fat in vitro and in vivo in mice, as well as the browning process in human white adipocytes.
57. Nedergaard J, Cannon B. How brown is brown fat? It depends where you look. Nature Medicine. 2013;19:540–541.
58. Ryden M, Backdahl J, Petrus P, et al. Impaired atrial natriuretic peptide-mediated lipolysis in obesity. Int J Obes (Lond). 2016;40:714–720.
59. Verboven K, Hansen D, Moro C, et al. Attenuated atrial natriuretic peptide-mediated lipolysis in subcutaneous adipocytes of obese type 2 diabetic men. Clin Sci (Lond). 2016;130:1105–1114.
60. Moro C, Pasarica M, Elkind-Hirsch K, et al. Aerobic exercise training improves atrial natriuretic peptide and catecholamine-mediated lipolysis in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2009;94:2579–2586.
61. Sengenes C, Stich V, Berlan M, et al. Increased lipolysis in adipose tissue and lipid mobilization to natriuretic peptides during low-calorie diet in obese women. Int J Obes Relat Metab Disord. 2002;26:24–32.
62. Inuzuka M, Tamura N, Yamada N, et al. C-type natriuretic peptide as a new regulator of food intake and energy expenditure. Endocrinology. 2010;151:3633–3642.
63. Yamada-Goto N, Katsuura G, Ebihara K, et al. Intracerebroventricular administration of C-type natriuretic peptide suppresses food intake via activation of the melanocortin system in mice. Diabetes. 2013;62:1500–1504.
64. Yamashita Y, Yamada-Goto N, Katsuura G, et al. Brain-specific natriuretic peptide receptor-B deletion attenuates high-fat diet-induced visceral and hepatic lipid deposition in mice. Peptides. 2016;81:38–50.
65. Vila G, Grimm G, Resl M, et al. B-type natriuretic peptide modulates ghrelin, hunger, and satiety in healthy men. Diabetes. 2012;61:2592–2596.
66. Lazo M, Young JH, Brancati FL, et al. NH2-terminal pro-brain natriuretic peptide and risk of diabetes. Diabetes. 2013;62:3189–3193.•• This is a prospective population-based study in 7822 patients showing that NT-proBNP independently predicts the risk of new-onset T2D.
67. Magnusson M, Jujic A, Hedblad B, et al. Low plasma level of atrial natriuretic peptide predicts development of diabetes:the prospective Malmo Diet and Cancer study. J Clin Endocrinol Metab. 2012;97:638–645.
68. Walford GA, Ma Y, Christophi CA, et al. Circulating natriuretic peptide concentrations reflect changes in insulin sensitivity over time in the Diabetes Prevention Program. Diabetologia. 2014;57:935–939.
69. Kim F, Biggs ML, Kizer JR, et al. Brain natriuretic peptide and insulin resistance in older adults. Diabet Med. 2016. doi:10.1111/dme.13139.
70. Jujic A, Nilsson PM, Engstrom G, et al. Atrial natriuretic peptide and type 2 diabetes development–biomarker and genotype association study. PLoS One. 2014;9:e89201.
71. Meirhaeghe A, Sandhu MS, McCarthy MI, et al. Association between the T-381C polymorphism of the brain natriuretic peptide gene and risk of type 2 diabetes in human populations. Hum Mol Genet. 2007;16:1343–1350.
72. Moro C. Natriuretic peptides and fat metabolism. Curr Opin Clin Nutr Metab Care. 2013;16:645–649.
73. Moro C, Jordan J, Birkenfeld AL, et al. NH2-terminal pro-brain natriuretic peptide and risk of diabetes. Diabetes. 2013;62:3189–3193.
74. Tsukamoto O, Fujita M, Kato M, et al. Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure. J Am Coll Cardiol. 2009;53:2070–2077.
75. Birkenfeld AL, Boschmann M, Engeli S, et al. Atrial natriuretic peptide and adiponectin interactions in man. PLoS One. 2012;7:e43238.
76. Nakanishi K, Nishida M, Yamamoto R, et al. Association between N-terminal pro-brain natriuretic peptide and adiponectin in healthy Japanese men. Clin Chim Acta. 2016;460:138–141.
77. Moro C, Klimcakova E, Lolmede K, et al. Atrial natriuretic peptide inhibits the production of adipokines and cytokines linked to inflammation and insulin resistance in human subcutaneous adipose tissue. Diabetologia. 2007;50:1038–1047.
78. Heinisch BB, Vila G, Resl M, et al. B-type natriuretic peptide (BNP) affects the initial response to intravenous glucose:a randomised placebo-controlled cross-over study in healthy men. Diabetologia. 2012;55:1400–1405.
79. Kovacova Z, Tharp WG, Liu D, et al. Adipose tissue natriuretic peptide receptor expression is related to insulin sensitivity in obesity and diabetes. Obesity (Silver Spring). 2016;24:820–828.
80. Lutz SZ, Hennige AM, Feil S, et al. Genetic ablation of cGMP-dependent protein kinase type I causes liver inflammation and fasting hyperglycemia. Diabetes. 2011;60:1566–1576.
81. Ropero AB, Soriano S, Tuduri E, et al. The atrial natriuretic peptide and guanylyl cyclase-A system modulates pancreatic beta-cell function. Endocrinology. 2010;151:3665–3674.
82. Addisu A, Gower WR, Jr., Landon CS, et al. B-type natriuretic peptide decreases gastric emptying and absorption. Exp Biol Med (Maywood). 2008;233:475–482.
83. Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013;17:819–837.
84. Kim M, Platt MJ, Shibasaki T, et al. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nature Medicine. 2013;19:567–575.
85. Asmar A, Simonsen L, Asmar M, et al. Renal extraction and acute effects of glucagon-like peptide-1 on central and renal hemodynamics in healthy men. American journal of physiology. Endocrinol Metabolism. 2015;2014:ajpendo 00429.
86. Asmar A, Simonsen L, Asmar M, et al. Glucagon-like peptide-1 does not have acute effects on central or renal hemodynamics in patients with type 2 diabetes without nephropathy. Am J Physiol Endocrinol Metab. 2016;310:E744–E53.
87. Birkenfeld AL, Adams F, Schroeder C, et al. Metabolic actions could confound advantageous effects of combined angiotensin II receptor and neprilysin inhibition. Hypertension. 2011;57:e4–e5.
88. Ayala JE, Bracy DP, Julien BM, et al. Chronic treatment with sildenafil improves energy balance and insulin action in high fat-fed conscious mice. Diabetes. 2007;56:1025–1033.
89. Caton PW, Nayuni NK, Kieswich J, et al. Metformin suppresses hepatic gluconeogenesis through induction of SIRT1 and GCN5. J Endocrinol. 2010;205:97–106.
90. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343–1350.•• This study from the Diabetes Prevention Program demonstrates the efficacy and major therapeutic effect of changes in lifestyle habits in the prevention of T2D.
91. Moro C, Pillard F, De Glisezinski I, et al. Training enhances ANP lipid-mobilizing action in adipose tissue of overweight men. Med Sci Sports Exerc. 2005;37:1126–1132.
92. Agustsson T, Ryden M, Hoffstedt J, et al. Mechanism of increased lipolysis in cancer cachexia. Cancer Res. 2007;67:5531–5537.